Form 10-Q REXAHN PHARMACEUTICALS, For: Mar 31

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Form 10-Q REXAHN PHARMACEUTICALS, For: Mar 31

Rexahn (RNN) Valuation Remains Compelling at Supinoxin, RX-3117 Phase 1 Milestones Near - Roth Capital

May 11, 2015 3:10 PM EDT

Roth Capital reaffirms its Buy rating and $3 price target on Rexahn Pharmaceuticals (NYSE: RNN) following Q1 results issued earlier. Rexahn posted Q1 loss of $0.02 per share, versus the consensus loss estimate of $0.03 per share.

Analyst Joseph Pantginis commented, RNN is nearing two clinical milestones with the anticipated data releases from the two dose-escalation... More

Rexahn Pharma (RNN) Tops Q1 EPS by 1c

May 11, 2015 9:06 AM EDT

Rexahn Pharma (NYSE: RNN) reported Q1 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03).

For earnings history and earnings-related data on Rexahn Pharma (RNN) click here.

... More